272 related articles for article (PubMed ID: 24946015)
1. Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.
Berman CL; Cannon K; Cui Y; Kornbrust DJ; Lagrutta A; Sun SZ; Tepper J; Waldron G; Younis HS
Nucleic Acid Ther; 2014 Aug; 24(4):291-301. PubMed ID: 24946015
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
Kim TW; Kim KS; Seo JW; Park SY; Henry SP
J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663
[TBL] [Abstract][Full Text] [Related]
3. OSWG Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics.
Berman CL; Barros SA; Galloway SM; Kasper P; Oleson FB; Priestley CC; Sweder KS; Schlosser MJ; Sobol Z
Nucleic Acid Ther; 2016 Apr; 26(2):73-85. PubMed ID: 26978711
[TBL] [Abstract][Full Text] [Related]
4. Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeutics.
Cavagnaro J; Berman C; Kornbrust D; White T; Campion S; Henry S
Nucleic Acid Ther; 2014 Oct; 24(5):313-25. PubMed ID: 25137397
[TBL] [Abstract][Full Text] [Related]
5. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.
Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S
Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186
[TBL] [Abstract][Full Text] [Related]
6. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics.
Vargas HM; Bass AS; Breidenbach A; Feldman HS; Gintant GA; Harmer AR; Heath B; Hoffmann P; Lagrutta A; Leishman D; McMahon N; Mittelstadt S; Polonchuk L; Pugsley MK; Salata JJ; Valentin JP
J Pharmacol Toxicol Methods; 2008; 58(2):72-6. PubMed ID: 18508287
[TBL] [Abstract][Full Text] [Related]
7. Oligo safety working group exaggerated pharmacology subcommittee consensus document.
Kornbrust D; Cavagnaro J; Levin A; Foy J; Pavco P; Gamba-Vitalo C; Guimond A
Nucleic Acid Ther; 2013 Feb; 23(1):21-8. PubMed ID: 23289535
[TBL] [Abstract][Full Text] [Related]
8. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
[TBL] [Abstract][Full Text] [Related]
9. Clinical expert panel on monitoring potential lung toxicity of inhaled oligonucleotides: consensus points and recommendations.
Alton EW; Boushey HA; Garn H; Green FH; Hodges M; Martin RJ; Murdoch RD; Renz H; Shrewsbury SB; Seguin R; Johnson G; Parry JD; Tepper J; Renzi P; Cavagnaro J; Ferrari N
Nucleic Acid Ther; 2012 Aug; 22(4):246-54. PubMed ID: 22809313
[TBL] [Abstract][Full Text] [Related]
10. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
Serabian MA; Pilaro AM
Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
[TBL] [Abstract][Full Text] [Related]
11. Benchmarking safety pharmacology regulatory packages and best practice.
Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
[TBL] [Abstract][Full Text] [Related]
12. OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides.
Berman CL; Antonsson M; Batkai S; Bosgra S; Chopda GR; Driessen W; Foy J; Hassan C; Hu XS; Jang HG; Meena ; Sanseverino M; Thum T; Wang Y; Wild M; Wu JT
Nucleic Acid Ther; 2023 Oct; 33(5):287-305. PubMed ID: 37590469
[TBL] [Abstract][Full Text] [Related]
13. Safety evaluation to support First-In-Man investigations I: kinetic and safety pharmacology studies.
Baldrick P
Regul Toxicol Pharmacol; 2008 Jul; 51(2):230-6. PubMed ID: 18501489
[TBL] [Abstract][Full Text] [Related]
14. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
[TBL] [Abstract][Full Text] [Related]
15. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
[TBL] [Abstract][Full Text] [Related]
16. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.
Vargas HM; Amouzadeh HR; Engwall MJ
Expert Opin Drug Saf; 2013 Jan; 12(1):91-102. PubMed ID: 23170873
[TBL] [Abstract][Full Text] [Related]
17. Methods in safety pharmacology in focus.
Pugsley MK; Gallacher DJ; Towart R; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2008; 58(2):69-71. PubMed ID: 18707009
[TBL] [Abstract][Full Text] [Related]
18. Neurofunctional test batteries in safety pharmacology - Current and emerging considerations for the drug development process.
Jackson SJ; Authier S; Brohmann H; Goody SMG; Jones D; Prior H; Rosch A; Traebert M; Tse K; Valentin JP; Milne A
J Pharmacol Toxicol Methods; 2019; 100():106602. PubMed ID: 31238094
[TBL] [Abstract][Full Text] [Related]
19. Methodology used in safety pharmacology: appraisal of the state-of-the-art, the regulatory issues and new directions.
Pugsley MK
J Pharmacol Toxicol Methods; 2005; 52(1):1-5. PubMed ID: 15982903
[TBL] [Abstract][Full Text] [Related]
20. Overview of safety pharmacology.
Porsolt RD
Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.1. PubMed ID: 22294166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
